U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C40H71NO14
Molecular Weight 789.99
Optical Activity UNSPECIFIED
Defined Stereocenters 18 / 18
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ERYTHROMYCIN PROPIONATE

SMILES

[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]2[C@H](C)[C@@H](O[C@]3([H])O[C@H](C)C[C@@H]([C@H]3OC(=O)CC)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]2C

InChI

InChIKey=TYQXKHPOXXXCTP-CSLYCKPJSA-N
InChI=1S/C40H71NO14/c1-15-27-40(11,48)33(44)22(5)30(43)20(3)18-38(9,47)35(55-37-32(53-28(42)16-2)26(41(12)13)17-21(4)50-37)23(6)31(24(7)36(46)52-27)54-29-19-39(10,49-14)34(45)25(8)51-29/h20-27,29,31-35,37,44-45,47-48H,15-19H2,1-14H3/t20-,21-,22+,23+,24-,25+,26+,27-,29+,31+,32-,33-,34+,35-,37+,38-,39-,40-/m1/s1

HIDE SMILES / InChI

Molecular Formula C40H71NO14
Molecular Weight 789.99
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 18 / 18
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Erythromycin ethylsuccinate (E.E.S.®, ERY-PED®) is an ester of erythromycin base and succinic acid. It is suitable for oral administration. Erythromycin is a macrolide antibiotic, produced by Saccharopolyspora erythraea (formerly Streptomyces erythraeus). It acts primarily as a bacteriostatic agent. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Erythromycin does not affect nucleic acid synthesis.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
14.0 nM [Kd]
14.0 nM [Kd]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Erythromycin
Curative
Erythromycin
Curative
Erythromycin
Curative
Erythromycin
Curative
Erythromycin
Curative
Davercin
Curative
Davercin
Curative
Davercin
Curative
Davercin
Curative
E.E.S.
Curative
E.E.S.
Curative
E.E.S
Curative
E.E.S.
Curative
E.E.S.

Cmax

ValueDoseCo-administeredAnalytePopulation
1.18 μg/mL
500 mg single, oral
ERYTHROMYCIN serum
Homo sapiens
2.44 μg/mL
500 mg single, oral
ERYTHROMYCIN serum
Homo sapiens
1.62 μg/mL
250 mg 4 times / day multiple, oral
ERYTHROMYCIN serum
Homo sapiens
1.99 μg/mL
250 mg 4 times / day multiple, oral
ERYTHROMYCIN serum
Homo sapiens
1161.5 ng/mL
200 mg single, oral
ERYTHROMYCIN unknown
Homo sapiens
1386.1 ng/mL
200 mg single, oral
ERYTHROMYCIN unknown
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
3.1 μg × h/mL
500 mg single, oral
ERYTHROMYCIN serum
Homo sapiens
6.1 μg × h/mL
500 mg single, oral
ERYTHROMYCIN serum
Homo sapiens
3544.7 ng × h/mL
200 mg single, oral
ERYTHROMYCIN unknown
Homo sapiens
4096.7 ng × h/mL
200 mg single, oral
ERYTHROMYCIN unknown
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
4.48 h
200 mg single, oral
ERYTHROMYCIN unknown
Homo sapiens
5.31 h
200 mg single, oral
ERYTHROMYCIN unknown
Homo sapiens

Doses

AEs

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer






Drug as perpetrator​

Drug as victim

Tox targets

PubMed

Sample Use Guides

In Vivo Use Guide
Initial dose - 30 mg/kg, then 15 mg/kg every 12 hours.
Route of Administration: Other
In Vitro Use Guide
At the concentration which stops polylysine synthesis by more than 80% (about 0.5 nM/100 pM of 70S ribosomes), the Erythromycin cyclocarbonate inhibited but slightly binding of phage f2 RNA to ribosomes.
Substance Class Chemical
Record UNII
HB75CIT999
Record Status Validated (UNII)
Record Version